The Absolute Effect / Oncology Evidence
Breast Cancer Trial Evidence
The Absolute Effect presents breast cancer trials in a clinically interpretable format, emphasizing what the treatment changes for patients rather than relative measures alone.
Featured evidence
- CALGB 9343 — radiotherapy omission in older women after lumpectomy and endocrine therapy.
- PRIME II — radiotherapy omission in older women with low-risk hormone-receptor-positive disease.
- NSABP B-04 — extent of breast and axillary surgery.
- NSABP B-18 — neoadjuvant chemotherapy before surgery.
- NSABP B-27 — neoadjuvant chemotherapy and pathologic response.
- DBCG 82b — postmastectomy radiotherapy in high-risk disease.
How to interpret the evidence
For each trial, look for the absolute difference at a specified time horizon, the endpoint used to calculate it, and the corresponding NNT or NNH when a defensible calculation is possible.